IDCRC Investigator Profile: Tara Reid, MD, PhD
This month's IDCRC investigator spotlight features Tara Reid, MD, PhD, assistant professor in the University of Washington's Department of Medicine, Division of Allergy & Infectious Diseases.
Dr. Reid is particularly interested in vaccinology to prevent sexually transmitted infections. Her previous work focused on bacterial pathogenesis and antigenic variation during syphilis infections. She is currently expanding on this work by defining T. pallidum specific T cell antigens during infection.
How long have you worked with a VTEU?
I joined the University of Washington VTEU in 2020 as an infectious diseases physician–scientist in the Division of Allergy and Infectious Diseases.
Can you share more about a current IDCRC study you're working on?
My research program focuses on understanding immune responses to Treponema pallidum, the bacterium that causes syphilis, with the goal of informing vaccine development. I was awarded an IDCRC pilot award in 2021 to support studies examining human immune responses to this pathogen and identifying potential vaccine targets. These studies integrate clinical samples with immunologic approaches to better understand protective immunity in humans and have lead to ongoing projects supported by a successful K08 application and Burroughs Wellcome Career Award for Medical Scientists.
Briefly describe the IDCRC-supported trials you’ve supported.
I participated in the 2020 Novavax COVID-19 vaccine trial through the VTEU network, which was an important effort to evaluate a novel protein-based vaccine platform during the pandemic. Participating in this trial provided valuable experience in collaborative clinical research and highlighted the importance of coordinated national trial networks in responding to emerging infectious diseases. I was able to build lasting connections through the VTEU network while experiencing firsthand, the impactful role of clinical research in our local communities.
Of these trials, what has been the most impactful or a highlight of the work?
Participating in the Novavax COVID-19 vaccine trial during the pandemic was particularly meaningful. It demonstrated how the VTEU and IDCRC networks can mobilize quickly to conduct rigorous clinical research during a public health emergency and generate data that informs vaccine development and policy.
What is a strength or example of the importance of the IDCRC?
One of the strengths of the IDCRC is its ability to support investigators at multiple stages of their careers while fostering collaboration across institutions. I was fortunate to participate in the inaugural IDCRC mentorship cohort and currently serve as a co-chair of the lecture series. These opportunities have been a rewarding way to engage with colleagues across the network.
What do you like to do outside of the VTEU?
Outside of work, I enjoy spending time with my family, reading, gardening, and exploring the Pacific Northwest. I also spend a lot of time traveling to my daughter’s volleyball tournaments and enjoying road trips together. These activities help me recharge and balance the pace of academic medicine.